The Economics of the Public Option: Evidence from Local Pharmaceutical Markets
American Economic Review · 01.03.2024 · 114 (3) · 615-644
DOI: 10.1257/aer.20211547 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Economic Review, erschienen am 01.03.2024. Verfasst von Juan Pablo Atal und 3 weiteren Autor:innen. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 82 Literaturangaben.
Abstract (Originalsprache)
We study the effects of competition by state-owned firms, leveraging the decentralized entry of public pharmacies to local markets in Chile. Public pharmacies sell the same drugs at a third of private pharmacy prices, because of stronger upstream bargaining and market power in the private sector, but are of lower quality. Public pharmacies induced market segmentation and price increases in the private sector, which benefited the switchers to the public option but harmed the stayers. The countrywide entry of public pharmacies would reduce yearly consumer drug expenditure by 1.6 percent. (JEL D22, I18, L32, L65, O14)
Zitieren
APA
Atal, J. P., Cuesta, J. I., González, F., & Otero, C. (2024). The Economics of the Public Option: Evidence from Local Pharmaceutical Markets. American Economic Review, 114(3), 615-644. https://doi.org/10.1257/aer.20211547
Vancouver
Atal JP, Cuesta JI, González F, Otero C. The Economics of the Public Option: Evidence from Local Pharmaceutical Markets. American Economic Review. 2024;114(3):615-644. doi:10.1257/aer.20211547
BibTeX
@article{Atal2024,
author = {Atal, Juan Pablo and Cuesta, José Ignacio and González, Felipe and Otero, Cristóbal},
title = {The Economics of the Public Option: Evidence from Local Pharmaceutical Markets},
journal = {American Economic Review},
year = {2024},
volume = {114},
number = {3},
pages = {615--644},
doi = {10.1257/aer.20211547}
}
EUVIMED